Page last updated: 2024-10-18

dalteparin and Purpura Fulminans

dalteparin has been researched along with Purpura Fulminans in 3 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Purpura Fulminans: A severe, rapidly fatal reaction occurring most commonly in children following an infectious illness. It is characterized by large, rapidly spreading skin hemorrhages, fever, or shock. Purpura fulminans often accompanies or is triggered by DISSEMINATED INTRAVASCULAR COAGULATION.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dogan, M1
Acikgoz, M1
Bora, A1
Başaranoğlu, M1
Oner, AF1
Rosenzweig, N1
Strauss, T1
Rubinstein, M1
Paret, G1
Kenet, G1
May, C1
O'Rourke, K1
Jackson, K1
Francis, L1
Kennedy, GA1

Other Studies

3 other studies available for dalteparin and Purpura Fulminans

ArticleYear
Varicella-associated purpura fulminans and multiple deep vein thromboses: a case report.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2009, Volume: 76, Issue:3

    Topics: Anticoagulants; Blood Coagulation Tests; Blood Component Transfusion; Chickenpox; Child; Glucocortic

2009
Activated protein C concentrate treatment for skin necrosis under warfarin treatment in severe genetic protein C deficiency combined with prothrombin mutation and factor V Leiden.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:2

    Topics: Anticoagulants; Blood Coagulation; Blood Component Transfusion; Child; Enoxaparin; Factor V; Humans;

2009
Purpura fulminans in a patient with paroxysmal nocturnal haemoglobinuria.
    Internal medicine journal, 2013, Volume: 43, Issue:1

    Topics: Amoxicillin; Anticoagulants; Blood Coagulation Tests; Citalopram; Contraindications; Drug Therapy, C

2013